University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Peter Sayre, Ph.D., M.D.

Blood disorder specialist

Dr. Peter Sayre specializes in adult bone marrow transplantation, hematology and treatment of leukemia, multiple myeloma, lymphoma and Hodgkin's disease. His research interests focus on allogeneic stem cell transplants and leukemia in older adults. His work on these subjects has been widely published in medical and scientific journals. In addition, Sayre is an assistant adjunct professor of medicine and director of clinical research at UCSF.

Sayre graduated magna cum laude with an undergraduate degree in philosophy from Yale College. He earned a medical degree at the Robert Wood Johnson Medical School of the University of Medicine and Dentistry of New Jersey as well as a doctorate in immunology at Harvard University. He completed a hematology-oncology fellowship at the University of California, San Francisco before joining the faculty in 1996.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave.,
Suite A-502
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051

Hours: Monday to Friday
8 a.m. – 5 p.m

Conditions & Treatments

More about Peter Sayre

Additional Languages

French
Spanish

Education

Robert Wood Johnson Medical School 1990

Residencies

UC San Diego, Internal Medicine 1993

Fellowships

UCSF, Oncology 1996
UCSF, Hematology 1996

Selected Research and Publications

  1. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov; 62(11):3766-74.
  2. Holt PG, Sly PD, Sampson HA, Robinson P, Loh R, Lowenstein H, Calatroni A, Sayre P. Prophylactic use of sublingual allergen immunotherapy in high-risk children: a pilot study. J Allergy Clin Immunol. 2013 Oct; 132(4):991-3.e1.
  3. Du Toit G, Roberts G, Sayre PH, Plaut M, Bahnson HT, Mitchell H, Radulovic S, Chan S, Fox A, Turcanu V, Lack G. Identifying infants at high risk of peanut allergy: the Learning Early About Peanut Allergy (LEAP) screening study. J Allergy Clin Immunol. 2013 Jan; 131(1):135-43.e1-12.
  4. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, Tchao N, Sayre P, Bianchine P. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun. 2010 Jun; 34(4):408-15.
  5. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009 Aug; 132(2):166-73.
  6. Sayre PH, Finer-Moore JS, Fritz TA, Biermann D, Gates SB, MacKellar WC, Patel VF, Stroud RM. Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases. J Mol Biol. 2001 Nov 2; 313(4):813-29.
  7. Lackey DB, Groziak MP, Sergeeva M, Beryt M, Boyer C, Stroud RM, Sayre P, Park JW, Johnston P, Slamon D, Shepard HM, Pegram M. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem Pharmacol. 2001 Jan 15; 61(2):179-89.
  8. Linker CA, Ries CA, Damon LE, Sayre P, Navarro W, Rugo HS, Rubin A, Case D, Crilley P, Topolsky D, Brodsky I, Zamkoff K, Wolfe JL. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant. 2000; 6(1):50-7.
  9. Chang CH, Scott GK, Kuo WL, Xiong X, Suzdaltseva Y, Park JW, Sayre P, Erny K, Collins C, Gray JW, Benz CC. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene. 1997 Apr 3; 14(13):1617-22.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.